Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 279 Triple Negative Breast Neoplasms 146 Neoplasm Metastasis 27 Ovarian Neoplasms 23 Carcinoma, Non-Small-Cell Lung 17 Inflammatory Breast Neoplasms 15 Pancreatic Neoplasms 12 Neoplasms 11 Endometrial Neoplasms 11 Breast Neoplasms, Male 11 Colorectal Neoplasms 8 Carcinoma, Ductal, Breast 8 Stomach Neoplasms 7 Parkinson Disease 4, Autosomal Dominant Lewy Body 7 Lung Neoplasms 7 Prostatic Neoplasms 6 Melanoma 6 Fallopian Tube Neoplasms 6 Uterine Cervical Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 5 Sarcoma 5 Pathologic Complete Response 5 HER2-positive Breast Cancer 5 Carcinoma, Ovarian Epithelial 5 Esophageal Neoplasms 4 Carcinoma, Lobular 4 Urinary Bladder Neoplasms 3 Small Cell Lung Carcinoma 3 Recurrence 3 Multiple Myeloma 3

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Cancer Related Cognitive Decline × Carboplatin × Breast × Clear all

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡